Value Microcaps Zip Code Changers

[Potse]

VODG(.133)..revenue acceleration, near-term profitability.....

I'm fully expecting to see some nice upward movement (either sustained or tradeable spikes/swings) in the stock at some point in calendar 2014 or the first quarter of 2015. Although the numbers might be relatively small, VODG has been experiencing a trend of accelerating revenue and the company appears to be fully intent on posting bottom-line profits by at least Q4 (August-October 2014).

VODG has been significantly increasing the breadth of its product offerings, as well as making changes to its overall business focus/approach. You can often get advance information on VODG developments by monitoring the various social media websites associated with Neuromics and Pete Shuster (VODG's product distributor and Director).

Excerpts from the last two press releases issued by VODG.....

1)

Golden, Colorado—May 6, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced completion of its second fiscal quarter. Revenues continue to show strong growth and the Company projects near-term attainment of profitable operations. Total revenues increased three-fold (300%) in the first six months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract research services. Our products include adult stem cells and several formulations of cell culture media for stem cell growth and differentiation. Our products have competitive advantages including out-performance of competitor’s products in several different aspects. We have recently added new products including cell lines and stem cell media products for culture of canine and equine stem cells. Revenue from products rose by 70% over the first 6 months of 2013.

Dr. Jim Musick, Vitro Biopharma’s President & CEO said, “We are very pleased to announce continued revenue growth during the first six months of 2014. This is a direct reflection of our increased collaboration with Neuromics, Inc. At the end of December we decided to defer our merger and focus instead on growing the revenue and earnings of Vitro Biopharma to profitability. This would result in positive earnings for the subsequent merger of the two companies. That plan has been operational since then and I am pleased to say that this is working quite well. We anticipate continued growth of revenues throughout 2014 and project profitable operations at the end of 2014. In addition we anticipate the establishment of platforms to accelerate revenues & earnings growth substantially through our regenerative medicine and drug discovery/development initiatives. Vitro Biopharma has relatively limited number of common shares issued and outstanding, approximately 20 million that is very modest for comparable companies. With our ability to generate earnings and rapid earnings growth, we anticipate strong earnings per share growth as we go forward which is one of the fundamental aspects of Vitro Biopharma. We have very actively attempted to maintain a favorable capital structure for the company.”

http://vitrobiopharma.com/2014/05/06/vitro-biopharma-revenues-continue-accelerate-towards-profitability/

2)

Pete Shuster, a Director of Vitro Biopharma and the CEO & founder of Neuromics said “The excellent work being done by Jim and his team has opened up two new and predictable revenue sources for Vitro Biopharma. First, the assays developed to test the potency of our stem cell activating agents are excellent for stem cell based drug discovery. These assays can be used to test small molecules/compounds, for cell-based drug delivery and toxicity studies. We have a wealth of data available to support our value proposition. We are in the process of developing a plan to make these assays available to biopharma companies in a way that best fits their requirements. Secondly, we have started generating revenue by providing these tested activators to select clients in Europe. Initial therapeutic value is encouraging pending more testing after 3-6 months of treatment. We have plans to ramp up our stem cell activating products rapidly pending results. We anticipate these developments will enable Vitro Biopharma become cash flow positive in Q3 and consistently profitable starting in Q4, 2014.

http://vitrobiopharma.com/2014/06/10/vitro-biopharma-announces-advances-stem-cell-therapy-without-transplants/